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Abstract
Background: Oxidoreductases are enzymes that catalyze many redox reactions in normal and neoplastic cells.
Their actions include catalysis of the transformation of free, neutral oxygen gas into oxygen free radicals,
superoxide, hydroperoxide, singlet oxygen and hydrogen peroxide. These activated forms of oxygen contribute
to oxidative stress that modifies lipids, proteins, DNA and carbohydrates. On the other hand, oxidoreductases
constitute one of the most important free radical scavenger systems typified by catalase, superoxide dismutase
and glutathione peroxidase.
In this work, proteomics, Gene Ontology mapping and Directed Acyclic Graphs (DAG) are employed to detect
and quantify differential oxidoreductase enzyme expressions between HepG2 cells and normal human liver
tissues.
Results: For the set of bioinformatics calculations whose BLAST searches are performed using the BLAST
program BLASTP 2.2.13 [Nov-27-2005], DAG of the Gene Ontology's Molecular Function annotations show
that oxidoreductase activity parent node of the liver proteome contains 331 annotated protein sequences, 7 child
nodes and an annotation score of 188.9, whereas that of HepG2 cells has 188 annotated protein sequences, 3
child nodes and an annotation score of only 91.9. Overwhelming preponderance of oxidoreductases in the liver
is additionally supported by the isomerase DAGs: nearly all the reactions described in the normal liver isomerase
DAG are oxidoreductase isomerization reactions, whereas only one of the three child nodes in the HepG2
isomerase DAG is oxidoreductase. Upon normalization of the annotation scores to the parent Molecular
Function nodes, oxidoreductases are down-regulated in HepG2 cells by 58%.
Similarly, for the set of bioinformatics calculations whose BLAST searches are carried out using BLASTP 2.2.15
[Oct-15-2006], oxidoreductases are down-regulated in HepG2 cells by 56%.
Conclusion: Proteomics and Gene Ontology reveal, for the first time, differential enzyme activities between
HepG2 cells and normal human liver tissues, which may be a promising new prognostic marker of Hepatocellular
carcinoma.
Two independent sets of bioinformatics calculations that employ two BLAST program versions, and searched 
different databases, arrived at essentially the same conclusion: oxidoreductases are down-regulated in HepG2 
cells by approximately 57%, when compared to normal human liver tissues. Down-regulation of oxidoreductases 
in hepatoma is additionally supported by Gene Ontology analysis of isomerises.
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Background
Hepatocellular carcinoma (HCC or hepatoma) is the
most common primary cancer of the liver [1]. It is the fifth
most common cancer worldwide with about one million
new diagnoses annually [1]. The seventh most common
cause of cancer deaths in men, and the ninth in women
[2], HCC accounts for nearly 80–90% of all liver cancers
[3]. It has been shown that more than 80% of individuals
with HCC have cirrhosis [4,5], and that hepatitis B virus
(HBV) [6], hepatitis C virus (HCV) [6] and aflatoxin B1
(AFB) [6] account for up to 80% of all HCCs [7]. To date,
the most widely recognized biomarker of HCC is alpha-
fetoprotein, which is elevated in the blood of nearly 70%
of patients diagnosed with this disease [8].
A distinctive pathological hallmark of Hepatocellular car-
cinoma is a dramatic down-regulation of oxidoreductase
enzymes (oxidoreductases) in the host, when compared
to matched healthy cohorts [9-27]. The genetic and bio-
chemical determinants underlying this phenomenon are
not known. Additionally, many structural and functional
abnormalities in oxidoreductases have been linked to
Hepatocellular carcinoma [9-27].
Oxidoreductase enzymes are key enzymes in pathways of
oxygen utilization in normal and neoplastic cells. Their
actions include the conversion of molecular oxygen to
oxygen free radicals, superoxide, hydroperoxide, singlet
oxygen and hydrogen peroxide. These activated forms of
oxygen contribute to oxidative stress that modifies lipids,
proteins, DNA and carbohydrates. Oxidoreductases also
constitute the most important free radical scavenger sys-
tems exemplified by catalase, superoxide dismutase and
glutathione peroxidise [19].
Repression of oxidoreductases in hepatoma has been con-
sistently documented in humans, animal models and cell
lines [9-27]. In one study, several oxidoreductase
enzymes, including cytochrome oxidase, succinate dehy-
drogenase, monoamine oxidase, urate oxidase, D-amino
acid oxidase, L-α-hydroxy acid oxidase, xanthine oxidase
and catalase, were examined; the enzyme activities of all
the oxidoreductase are steeply reduced in hepatoma,
when compared to controls [15]. Other work [18-
24,27,28] show that, in Hepatocellular carcinoma, the
natural free radical scavenger systems of oxidoreductase
enzymes that protect cells from oxidative stress, apoptosis
and other damaging effects of oxygen free radicals, are
strongly compromised. Sierra-Rivera and co-workers [22]
noted that the decline in enzymatic activities of CuZn-
SOD, MnSOD and catalase in hepatoma was due to a
decline in the levels of immunoreactive proteins. Another
study [11] found that cytochrome oxidase was about 60%
lower in whole-cell suspensions of Morris hepatoma
3924A than in whole-cell suspensions of normal or host
rat liver. Weber and co-workers [13,14] observed that xan-
thine oxidase, the key rate-limiting enzyme of purine
catabolism, was decreased 2- to 10-fold in all hepatomas
studied, regardless of the degree of malignancy, growth
rates and degrees of the histological differentiation of the
neoplasms.
A wide range of enzyme assays and other experimental
methods have been employed to study oxidoreductase
enzymes in Hepatocellular carcinoma. They include:
reverse transcriptase polymerase chain reaction amplifica-
tion [25,26], immunohistochemical staining [25,26,28],
in-situ hybridization [25], and Western blotting [26,28].
Many oxidoreductase enzyme assays incorporate spectro-
scopic absorbance [11,13,15,28] and polarography [11].
Other utilize RNA blot hybridization [21], run-on assays
[21] and Lowry protein assays [11,15].
Although the above experimental methods have contrib-
uted immensely to better understanding of the pathobiol-
ogy of oxidoreductase enzymes in hepatic neoplasia, they
all suffer from lack of specificity in the structural informa-
tion they provide (for example, specific posttranslational
modifications of proteins), ability to analyze sample mol-
ecules in the presence of interfering contaminants and
ability to map the broad cellular biology and biophysical
profiles of the tumor vs. matched benign cohorts.
To date, no proteomics method for oxidoreductase
enzymes in Hepatocellular carcinoma has been attempted
or documented. The mass spectrometry-based proteomic
approach presented in this work holds the potential to
overcome all of the above limitations, in addition to pro-
viding improved ease of automation, speed and sensitiv-
ity.
HepG2 cell line, rather than hepatoma, is chosen for pro-
teomic comparison with normal human liver in this work.
The reason for choosing a cell line is because heterogene-
ity inherently associated with complex liver tumor matrix,
which could be further compounded by cirrhosis, hepati-
tis B virus, Hepatitis C virus, inflammation, regenerative
liver fibrosis and other lesions, may introduce inordinate
errors.
Unique challenges posed by the heterogeneity of complex
liver tumor matrix is attested by the work of Fernandez
and co-workers [29], who clearly showed that the varia-
tion within adenocarcinoma tissue samples is considera-
bly greater than that within the matched benign cohorts.
Therefore, HepG2 cell line is chosen for this study prima-
rily because it is more homogenous. However, tumor cell
lines do not always accurately represent the in vivo biolog-
ical profiles of the tumor tissues from which they are
derived. For example, Sandberg and co-workers [30]Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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found that only 34 of the 60 cell lines used in a quantita-
tive tissue similarity index analysis were most similar to
the tumor types from which they were derived. In a study
[31], freshly dissected non-cultured HLE cells from both
central and peripheral lens epithelia were found to exhibit
different protein expression patterns compared to corre-
sponding immortalized HLE B-3 cell line.
Sometimes, however, the protein expression profiles of
cell lines do represent the accurate protein expression pro-
files of the in vivo tumor or tissues. Indeed, immortalized
cell lines derived from human tumors, like HepG2 cell
line, are more homogenous than solid liver tumors, as
noted above. They have been extensively employed in a
wide range of in vitro disease models, and they produce
large amounts of high quality DNA, mRNA and protein
for analysis. Furthermore, they are excellent tools for
mechanistic studies and are commercially available. Addi-
tionally, they afford improved reproducibility, ease of
application of quantitative techniques and controlled
experimental conditions. In addition, the protein profiles
of cell cultures tend to give cleaner backgrounds than
those of the corresponding tissues.
Wirth and co-workers [32] provide an example where a
cell line reflects a true representation of the in vivo biology:
they reported that proteins present in non-transformed
cell lines Chang and WRL-68 were identical to the pro-
teins found in normal human liver. And, in a proteome
profiling study, fresh bladder tumors showed strikingly
similar protein expression profiles when compared to
their primary cell cultures [33]. Furthermore, Didonato
and co-workers[34] compared the protein expressions of
renal cell carcinoma (RCC) tissues and patient-matched
normal kidney tissues with the primary RCC renal cell cul-
tures derived from the tissues, and found that the overall
patterns of the profiles of the tissues and cell cultures were
similar. The protein spots on the 2D-PAGE of the cell cul-
tures had much higher resolution, and the exact expres-
sion alterations of proteins in cancer and normal cell
cultures were present in the tissue samples. Tan and co-
workers [35] examined an immortalized mouse retinal
cell line (661W) for markers characteristic of photorecep-
tor cells; they found that the 661W cell line exhibited sim-
ilar cellular and biochemical characteristics to those of the
original cone photoreceptor cells from which they were
derived. In a T-cell acute lymphoblastic leukemia study,
Gjerset and co-workers [36] found that, with regard to sur-
face markers, karyotype, and T-cell receptor gene rear-
rangements, the cell cultures indeed closely resembled
those of the patients at the time of diagnosis.
Comparative proteomics of a normal tissue against those
of its tumor cell line could afford useful insights into qual-
itative and quantitative changes in proteins profiles fol-
lowing tumor development, and facilitate the discovery of
novel markers of tumors. Loredana and co-workers [37]
profiled the proteome of normal human breast tissues,
and compared these with those of the corresponding
8701-BC breast cancer cell line (ductal infiltrating carci-
noma, DIC). They found that the 8701-BC cell line retains
the dominant luminal phenotype of the breast epithe-
lium, which expresses predominantly cytokeratins -8 and
-18, and that the proteomic profile of the cell line appears
highly homologous to the in vivo counterpart. Emili and
co-workers [38] performed a comparative proteomics of
protein expression patterns in proliferating MCF-7 breast
cancer cells and normal human mammary epithelial cells
using gel-free shotgun proteomics. They observed impor-
tant differences in the levels of key regulators of the cell
cycle, signal transduction, apoptosis, transcriptional regu-
lation, and cell metabolism.
The benefits of using cancer cell lines in cancer research
are clearly demonstrated by the In Vitro Cell Line Screen-
ing Project (IVCLSP) at the National Cancer Institute's
Developmental Therapeutics Program http://
dtp.nci.nih.gov/branches/btb/ivclsp.html. The IVCLSP
screens up to 3,000 drug compounds every year for poten-
tial anticancer activity, using 60 different human tumor
cell lines, representing leukemia, melanoma and cancers
of the lung, colon, brain, ovary, breast, prostate, and kid-
ney. The success of this program can only mean that cell
lines do provide valuable biological data, and sometimes,
accurate representation of the in vivo biology of tumors.
The present study was designed to employ multidimen-
sional protein identification technology (MudPIT) pro-
teomics, Gene Ontology mapping and directed acyclic
graph representations to detect, compare and contrast
qualitative and quantitative oxidoreductase enzyme
expression profiles of the HepG2 proteome vs. that of a
normal human liver.
Two independent sets of bioinformatics calculations that
employ two BLAST program versions, and searched differ-
ent sets of databases, arrived at essentially the same con-
clusion – that oxidoreductases are down-regulated in
HepG2 cells by an average of 57%, when compared to
normal human liver tissues.
Methods
Samples
HepG2 cell lysates (RDI-HepG2-CPX Lot#HEPG2/3b),
500 μg in 0.5 mL (1 mg/mL) in SDS-PAGE Buffer (62 mM
Tris pH6.8, 2% SDS, 0.9% β-mercaptoethanol, 0.003%
bromophenol blue, 5% glycerol), and normal human
liver tissue lysates (RDI-NLH-01 Lot #NLH01/082604a),
150 μg in 0.032 mL (5 μg/μL) denaturing buffer with pro-
teolytic inhibitors to minimize proteolytic damage to pro-Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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teins, all lysates extracted by the method of Laemmli [39],
were obtained from RDI Division of Fitzgerald Industries
Intl (Concord, MA) and stored at -80°C until use. Prior to
use, the lysates are aliquotted into 100 μg total protein
portions and stored at -80°C. A 100 μg aliquot is used for
each experiment.
Under the auspices of Virginia Commonwealth University
Office of Research Subjects Protection, compliance with
U.S. Department of Health and Human Services (Office
for Human Research Protection) regulations at 45 CFR
46.101(b)(4) was provided by Fitzgerald Industries.
2D cleanup
Proteins are separated from buffers, detergents, salts and
other contaminants using a 2D clean-up kit and protocol
provided by Amersham Biosciences (GE Healthcare, Pis-
cataway, NJ). The kit consists of four reagents: a precipi-
tant that pellets the proteins, a co-precipitant that
enhances the removal of the proteins from the solution, a
wash buffer that removes non-protein contaminants from
the protein precipitate, and a wash additive that promotes
rapid and complete re-suspension of the proteins.
Prior to the beginning of clean-up, the wash buffer was
chilled at -20°C for 1 hr. After thawing and spinning
down 100 μg aliquots of HepG2 cell lysates and normal
human liver tissue lysates, 300 μL precipitant was added.
The mixture was vortexed on Eppendorf Thermomixer R
(Eppendorf North America, Westbury, NY), and then
incubated in ice for 15 minutes. Next, 300 μL of co-precip-
itant was added and the mixture mixed. The mixture was
centrifuged at 12000 × g for 5 minutes to pellet the pro-
teins. The clear supernatant liquid was carefully pipetted
out while retaining the protein precipitate at the bottom
of the 1.5 mL Eppendorf tube. Without disturbing the pel-
let layer, 40 μL of co-precipitant was added to the top of
the pellet; the mixture was kept in ice for 5 minutes before
centrifuging it again at 12000 × g for another 5 minutes.
The pellet was dispersed by adding 25 μL of MilliQ water
and centrifuging for 10 minutes. After adding 1 mL of
chilled wash buffer at -20°C and 5 μL of wash additive,
the mixture was vortexed once every 30 seconds for a total
of 35 minutes. At this point, the proteins did not dissolve,
but dispersed. The mixture was again centrifuged at 12000
× g for 5 minutes. The supernatant was carefully dis-
carded, and the pellet dried. The pellets are amorphous.
In-solution digestion
The dried pellet was re-suspended in 20 μL 8 M urea/100
mM ammonium bicarbonate (ABC), and 0.6 μL of 100
mM Dithiothreitol (DTT) in 100 mM ABC (i.e. 3 mM
DTT) was stirred in Eppendorf Thermomixer R for 1 hr at
29°C. After adjusting to room temperature, 1.5 μL of 200
mM iodo-acetamide (IAA) in 100 mM ABC (final concen-
tration of 15 mM IAA) was added. Alkylation was then
carried out by incubating the mixture for 45 minutes in a
darkroom. Then 1.5 μL of 200 mM DTT/100 mM ABC was
added to consume any un-reacted IAA. The urea concen-
tration was reduced to about 1 M by diluting the mixture
with 140 μL of (50 mM ABC+2 mM CaCl2). Digestion was
carried out by adding 6 μL of 0.40 μg/μL = 2.4 μg of
Promega Sequencing Grade trypsin and incubating in
Eppendorf Thermomixer R for 20 hr at 37.4°C. At the end
of the 20-hour incubation, the reaction was stopped by
adding 4.0 μL of 2% acetonitrile, and 6 μL of 10% TFA was
added to adjust the pH to 5.0.
Desalting
Manual, Micro Trap desalting cartridge and protocol from
Michrom (Michrom BioResources, Auburn, CA) were
used. First, the microTrap was washed with 80 μL of LC/
MS Solvent B (90%ACN/0.1% TFA). Next, it is equili-
brated with 80 μL of LCMS Solvent A (2%ACN/0.1%
TFA). Then, 20 μL of peptide digest sample is loaded onto
the microTrap; salts are removed by washing with 50 μL
aliquots of LCMS solvent A (2%ACN/0.1% TFA). Tryptic
peptides are eluted from the micro Trap with 16 μL of
70% ACN. Desalted peptides are evaporated to dryness on
an SC2 SpeedVAC® Plus Thermo savant (Thermo Fisher
Scientific, Waltham, MA).
Nanospray
The nanospray is a Paradigm Nanotrap Platform
equipped with a Paradigm Metal spray needle. The spray
tip is a 7.5 cm long, 30 μm (Internal Diameter) × 105 μm
(Outer Diameter) surgical stainless steel, electrochemi-
cally cut and polished, and sheathed by a 125 μm PEEK
Tubing. The needle is electrochemically cut and polished.
It permits flow range of 0.5 to 10 μL/min, and a voltage
range of 1000 to 5000 Volts. A 1/16" stainless steel Valco
nut attaches the spray needle to a 1/16" to 1/16" Valco
union, which is mounted on the Nanotrap platform.
Nanospray source parameters
Sheath Gas Flow Rate = 0; Aux Gas Flow Rate = 0; Spray
Voltage (kC) = 2.51; Spray Current (μA) = -0.05; Capillary
Temp (°C) = 221.10; Capillary Voltage (V) = 9.22; Tube
Lens Offset (V) = 50.
Multidimensional nano-HPLC
The nano-HPLC is a Paradigm MS4B Multi-Dimensional
HPLC equipped with a Michrom Paradigm AS1 refriger-
ated autosampler and XCalibur software plugin
(Michrom BioResources, Auburn, CA). It is configured
and operated in a 3-1 column-switching arrangement.
Pump D is used for sample loading on captrap cartridge
(sample concentration and de-salting) at 50 μL/minute
for 5 minutes.Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Columns (Michrom BioResources)
￿ Peptide Nanotrap (TR5/25109/42): 150 μm × 50 mm;
400 nL volume.
￿ Nanotrap analytical column (CL5/61241/00): 5 μm 200
Magic C18 75 μm × 150 mm.
￿ SCX Captrap (TR1/25108/35): Contains a medium
pore, large particle, silica-based strong cation exchange
material (PolySulfoethyl Aspartamide). Binds protein
digests, peptides, and other molecules (0.5–50 kD) for 1D
or 2D analysis; concentrates samples up to 100 fold (pH
range 2.7–7.0).
Nano-LC/ESI-MS/MS
One-dimensional (1D) and two-dimensional (2D) nano
HPLC experiments are run at a flow rate of 300 nL/min.
Samples are loaded onto trap columns for concentration
and desalting at 50 μL/min. For each experiment, 12 μL of
peptide digest resulting from 100 μg total protein is used:
2 μL is injected for 1D; 10 μL for 2D. Each shotgun exper-
iment consists of a 12-cycle MudPIT run in which a 60-
minute nano-LC gradient is run for each of: 1D, 2D, 2D (0
mM NH4COO), 2D (25 mM NH4COO), 2D (50 mM
NH4COO), 2D (75 mM NH4COO), 2D (100 mM
NH4COO), 2D (150 mM NH4COO), 2D (200 mM
NH4COO), 2D (250 mM NH4COO), 2D (300 mM
NH4COO) and 2D (500 mM NH4COO).
Mass spectrometry
Data-dependent MS and MS/MS spectra are acquired on
an LCQ Deca Xp plus (Thermo Fisher Scientific, San Jose,
CA).
MS and MS/MS
Five scan events are recorded for each data acquisition
cycle. The first scan event is used for full scan MS acquisi-
tion from 300–1800 m/z. Data are recorded in the cent-
riod  mode only because the first scan event does not
permit profile mode for data acquisition. The remaining
four scan events are used for collisionally activated disso-
ciation: the four most abundant ions in each MS are
selected and fragmented to produce product ion mass
spectra. All tandem spectra are recorded in the profile
mode.
MS/MS parameters
Number of microscans: 4; Maximum Injection Time (ms):
200; Isolation width (m/z): 3; Normalized Collision
Energy (%): 35; Activation Q: 0.250; Activation Time
(msec): 30.00; Scan Range: 300–1800 m/z.
Database searches and protein identification
Proteins are identified by searching the MS/MS spectra
against NCBI nr human fasta, using Bioworks v3.2
(Thermo Fisher Scientific, San Jose, CA). The Unified
Search Results File format (*.SRF) is employed, rather
than the traditional SEQUEST *.DTA and *.OUT formats.
Peptide and protein hits are scored and ranked using the
new probability-based scoring algorithm and the new
Final Score (Sf) that are incorporated in Bioworks 3.2.
Because MS/MS spectra are acquired in the profile mode,
each Nano-LC/ESI-MS/MS run range in size from 95 – 120
Megabytes, depending on the number of microscans (typ-
ically 4 ms) in the Advanced Define Scan function in the
MS/MS LCQtune file of the Instrument Method.
Filters
Only peptides identified as possessing fully tryptic termini
(containing up to two missed internal trypsin cleavage
sites), with cross-correlation scores (Xcorr) greater than 1.9
for singly charged peptides, 2.3 for doubly charged pep-
tides and 3.75 for triply charged peptides, are used for
peptide identification. In addition, the delta-correlation
scores (ΔCn) must be greater than 0.1 for peptide identifi-
cation.
With protein probability set at ≤ 1e-002, the 77831 origi-
nal hits (i.e. using the default filter settings) returned by
Bioworks 3.2 on the HepG2 proteome are reduced to
1795 validated, unique proteins (Additional File 1). Sim-
ilarly, 1819 validated, unique proteins (Additional File 2)
are obtained from 79961 original hits of the normal
human liver proteome.
Gene ontology
Gene ontology (Michael Ashburner [40,41]) analyses are
carried out with Blast2GO [42]http://
web3.vs160142.vserver.de/; a java webstart-enabled Gene
Ontology annotation, visualization and analysis program.
The 1024 MB option of Blast2GO was installed. The cal-
culations, as implemented here, consist of three key
sequential steps: (a) Basic Local Alignment Search Tool
(BLAST) [43,44], (b) Mapping and (c) Annotation.
All calculations are carried out on "Medusa," a high per-
formance dual tower, 64-node Beowulf cluster having 32
Gigabytes of SDRAM and 1 Terabyte of storage. Medusa is
located at the Bioinformatics Computational Core Labo-
ratory at Virginia Commonwealth University's Center for
the Study of Biological Complexity.
a) BLAST: In BLAST [43], protein input queries are sub-
mitted to the BLAST server at the National Center for Bio-
technology Information (NCBI) of the National Institutes
of Health (NIH) over the internet http://
www.ncbi.nlm.nih.gov/blast/Blast.cgi. The BLAST server
generates hits (hit gene ids (gi) and gene names/acces-
sions; 40 hits for each query; eValue Cutoff = 0.001)
needed for the Mapping step (below). The BLAST serverProteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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accepts only fasta-formatted protein sequences as input
query.
The 1795 HepG2 proteins and the 1819 normal human
liver proteins are converted into fasta formats and submit-
ted to NIH-NCBI BLAST server for calculations. The BLAST
server generates a Blast Table for each of the 1795 HepG2
and 1819 normal human liver proteins. The Blast Table
contains the results of the calculations: Sequences produc-
ing significant alignments, Gene Name, ACCESION #, e-
Value, align-length, positives, similarity %, hsps, mapping
and UniProt. These results are then input to the Mapping
algorithm (below).
b) Mapping: The mapping algorithm uses the parameters
of the Blast Table to search various databases to identify
and retrieve Gene Ontologies (GO) associated with the
hits obtained from NCBI BLAST searches. The results of
Mapping are presented in a Sequence Table, which con-
sists of nine parameters: Sequence name, Seq description,
Length, #hits, Maximum eValue, Similarity mean, #GOs
found, #GO IDs, Enzyme (i.e. Enzyme Commission #).
c) Annotation: The annotation procedure selects the GO
terms from the GO pool obtained by the Mapping step
and assigning them to the query sequences, using Annota-
tion Rule. Annotations are validated and expanded using
an annotation expander. The expander deploys an addi-
tional Gene Ontology structure: the Second Gene Ontol-
ogy layer, to suggest new Biological Processes and Cellular
Components, based on the gene's existing Molecular
Function annotations.
Gene Ontology (GO) is a consortium comprising some of
the world's major animal, plant and microbial databases
of genes and gene products, whose key objective was to
provide a coherent, species-independent platform for
accurate descriptions of gene products across different
databases.
Central to the Gene Ontology project are three structured
controlled vocabularies known as Ontologies. Ontologies
describe gene products in terms of their associated Biolog-
ical Processes (BP), Molecular Functions (MF) and Cellu-
lar Components (CC). A Biological Process is a set
biochemical actions accomplished by one or more
ordered assemblies of Molecular Functions, while Molec-
ular Function itself is the specific, elemental task per-
formed by individual gene products or assembled
complexes of gene products. GO molecular function
terms represent biological activities (not the molecular
entities that perform the task; they do not specify the time
or cellular site or in what context the action takes place.
Cellular Component Ontology, as the name implies,
describes the cellular sites, at the levels of sub-cellular
structures and macromolecular complexes, where the
gene product is found.
Results of a Gene Ontology analysis are presented in the
form of Directed Acyclic Graph (DAG). A DAG is a hierar-
chical representation of Ontology terms in a way that
depicts the directional relationships between parent-child
GO term nodes. A DAG differs from a simple hierarchy
graph in that a child (or more specialized term) may have
more than one parent.
There are two types of relationships between the terms in
parent-child child nodes of DAG. A child node that repre-
sents a more specific instance of a parent node is desig-
nated as 'is a' whereas 'part of' denote a child term node
that is a constituent of the parent node term. The 'part of'
is slightly more complicated than the 'is a' relationship.
For example, A 'part of' B means that whenever A is
present, it is always a part of B, but A does not always have
to be present. Example, nucleus is 'part of' a cell (nuclei
are always part of a cell) but not all cells have nuclei.
Every Gene Ontology annotation must provide valid evi-
dence, known as Evidence Codes (EC), which was used to
support it. Evidence codes encompass a broad range of
empirical or other support such as electronic annotation
or direct assay.
Results
The HepG2 dataset (Additional File 3, A) consists of
twelve MudPIT mass spectra (one 1D Nano-LC/ESI-MS/
MS and eleven 2D Nano-LC/ESI-MS/MS). Similarly, the
normal human liver dataset (Additional File 3, B) has
twelve MudPIT mass spectra. All mass spectra, with the
exception of two HepG2 chromatograms (obtained with
0.0 mM NH4COO- and 25.0 mM NH4COO-, respectively),
show strong chromatograms with reasonable elution pro-
files, good signal/noise ions and reproducibility.
As discussed in the Methods Section above, Mapping uses
parameters of the Blast Table to search and retrieve
Ontologies from various databases. The results are pre-
sented in a Sequence Table. The Sequence Tables for
HepG2 and Normal Human Liver proteomes, for the set
of analyses using the Blast program BLASTP 2.2.13 [Nov-
27-2005], are shown in Additional Files 4 and 5, for
HepG2 and Normal Human Liver, respectively. Mapping
also returns DB-Resources of Mapping, shown here in Fig-
ure 1, for HepG2 (Panel A) and Normal Human Liver
(Panel B), respectively.
In the HepG2 proteome, (Figure 1A), gene Ontologies are
found in three databases: GR, UniProt and UNIPROT,
whereas in the normal human liver proteome (Figure 1B),
Ontologies are found in eleven databases:Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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DB-Resources of Mapping, for HepG2 (Panel A), and Normal Human Liver (Panel B), showing the databases where mapping  found the Ontologies shown in Additional Files 4 and 5, respectively. BLAST searches were carried out with BLASTP 2.2.13  [Nov-27-2005] Figure 1
DB-Resources of Mapping, for HepG2 (Panel A), and Normal Human Liver (Panel B), showing the databases 
where mapping found the Ontologies shown in Additional Files 4 and 5, respectively. BLAST searches were carried 
out with BLASTP 2.2.13 [Nov-27-2005].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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GeneDB_Tbrucei, RGD, TAIR, SGD, UNIPROT, GR, FB,
WB, MGI, UniProt and ZFIN. In addition, HepG2 pro-
teome contains more Ontologies than normal human
liver proteome. Figure 2 shows the distribution of the evi-
dence codes for the HepG2 (Panel A) and normal human
liver (Panel B) proteomes. The distributions are clearly
characterized by diversity in EC, and dominated by trace-
able author statement (TAS), inferred from electronic
annotation (IEA), and inferred from direct assay (IDA);
these being the topmost ranks in the hierarchy of evidence
codes [45].
In Figure 3, the catalytic activity DAG of the HepG2 pro-
teome (Seqs:707 Score:161.8) has six level 2 child nodes
corresponding to the six main classes of enzymes: trans-
ferase (Seqs:183 Score:48.25), lyase (Seqs:63
Score:30.13), ligase (Seqs:52 Score:21.00), oxidoreduct-
ase (Seqs:188 Score:91.94), hydrolase (Seqs:314
Score:41.02) and isomerases (Seqs:73 Score:28.66).
On the other hand, the catalytic activity DAG of the nor-
mal human liver proteome (Seqs:886 Score:219.0) (Fig-
ure 4), has five child nodes: transferase (Seqs:227
Score:60.64), oxidoreductase (Seqs:331 Score:188.9),
hydrolase (Seqs:292 Score:43.83), isomerases (Seqs:74
Score:29.18), and lyase (Seqs:83 Score:23.12).
On the basis of the resulting normalized annotation
scores, it is seen that the overall catalytic activity is lower
in HepG2 by 36%, despite the fact that more HepG2 pro-
teins are annotated: HepG2: (Molecular Function:
Seqs:1738 Score:1122.0; Catalytic activity, Seqs:707
Score:161.8) :: Liver: (Molecular Function: Seqs:1555
Score:967.1; Catalytic activity, Seqs:886 Score:219.0)].
Most importantly, normalized scores reveal that oxidore-
ductase enzymes are down-regulated in HepG2 cells by
58%: HepG2: (oxidoreductase activity, Seqs:188
Score:91.94) :: Liver: (oxidoreductase activity, Seqs:331
Score:188.9)]. Expanded views of the oxidoreductase
DAGs are shown in Figure 5. Here, the node filter is fixed
at 30 for both HepG2 and liver DAGs for an unbiased
comparison.
A node filter is a means of simplifying the DAG: all nodes
with 30 or lower protein sequences are not shown. It is
seen that only three child nodes are observed for HepG2
oxidoreductase: monooxygenase activity (Seqs:38
Score:39.36), oxidoreductase activity, acting on CH-OH
group of donors (Seqs:68 Score:46.00), and GO:0016491
(Seqs:5). The normal liver oxidoreductase, on the other
hand, has seven child nodes, and whose sequences and
scores are even greater: oxidoreductase activity, acting on
CH-OH group of donors (Seqs:132 Score:120.0), oxidore-
ductase activity, acting on paired electron donors, with
incorporation or reduction of molecular oxygen (Seqs:49
Score:27.48), monooxygenase activity(Seqs:46
Score:32.97), oxidoreductase activity, acting on the alde-
hyde or oxo group of donors (Seqs:58 Score:32.47), elec-
tron carrier activity (Seqs:32 Score:24.06), GO:0016491
(Seqs:16), and oxidoreductase activity, acting on CH-CH
group of donors (Seqs:80 Score:22.94). In addition, a fur-
ther lowering of the node filter on HepG2 oxidoreductase
did not unveil additional child nodes that were previously
cut off, whereas only a slight lowering of the node filter on
normal liver oxidoreductase uncovers a large number of
previously hidden child nodes, making the chart very
complicated.
Down-regulation of oxidoreductases in HepG2 cells is
additionally supported by the isomerase DAGs (Figure 6),
where intramolecular oxidoreductase activity is 39%
higher in the normal liver: [HepG2: (intramolecular oxi-
doreductase activity, Seqs:25 Score:9.0) :: Liver: (intramo-
lecular oxidoreductase activity, Seqs:41 Score:14.76)]. In
addition, all the reactions described in the liver isomerase
are oxidoreductase reactions, whereas only one of the
three child nodes in the HepG2 isomerase DAG is oxi-
doreductase.
These findings can only mean that oxidoreductase
enzymes are down-regulated in HepG2 cells, when com-
pared to normal human liver. (cf. HepG2 contains even
more annotated protein sequences than the normal liver,
as discussed previously).
The percentages referred to in the above paragraphs are
those of normalized annotation scores. Normalization
allows for sequence-independent comparison of the
HepG2 and normal Human liver annotations: catalytic
activities are expressed as percentages of the total Molecu-
lar Function sequences and scores at the parent node (i.e.
HepG2: (Molecular Function: Seqs:1738 Score:1122.0 ::
Liver: (Molecular Function: Seqs:1555 Score:967.10))].
Validation
An additional step was taken to verify the down-regula-
tion of oxidoreductases in HepG2: the BLAST and Map-
ping experiments were repeated under a different set of
experimental conditions.
Here, a new BLAST program, BLASTP 2.2.15 [Oct-15-
2006] was used. The preceding BLAST searches were car-
ried out with BLASTP 2.2.13 [Nov-27-2005], as dis-
cussed. The results from the BLAST calculations are used
in the mapping step to search databases for Ontologies
belonging to the BLAST hits. With BLASTP 2.2.15 [Oct-
15-2006], mapping now includes NCBI RefSeq database
ftp://ftp.ncbi.nih.gov/refseq/release/, and Ontologies are
found in four databases: GR, UniProt, UNIPROT and Ref-Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Distribution of evidence codes that are found by Mapping, for the HepG2 and normal human liver proteomes, respectively Figure 2
Distribution of evidence codes that are found by Mapping, for the HepG2 and normal human liver proteomes, 
respectively. These are for the set of bioinformatics analyses whose BLAST searches were carried out using BLASTP 2.2.13 
[Nov-27-2005]. IC: Inferred by Curator, IDA: Inferred from Direct Assay, IEA: Inferred from Electronic Annotation, IEP: 
Inferred from Expression Pattern, IGC: Inferred from Genomic Context, IGI: Inferred from Genetic Interaction, IMP: Inferred 
from Mutant Phenotype, IPI: Inferred from Physical Interaction, ISS: Inferred from Sequence or Structural Similarity, NAS: Non-
traceable Author Statement, ND: No biological Data available, TAS: Traceable Author Statement, NR: Not Recorded.Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Seq (Figure 7 (Panels A and B)); Ontologies found in this
mapping are much less – essentially half of the number
found previously in Figure 1 (Panels A and B).
The distribution of evidence codes generated from the
bioinformatics based on BLASTP 2.2.15 [Oct-15-2006]
(Figure 8 (Panels A and B)) show very different profiles
than those of BLASTP 2.2.13 [Nov-27-2005] of Figure 2.
The Sequence Tables, shown in Additional Files 6 and 7,
for HepG2 and normal human Liver proteomes, respec-
tively, are also vastly different from those of BLASTP
2.2.13 [Nov-27-2005].
The catalytic activity DAG of the HepG2 proteome
(Seqs:671 Score:161.7) (figure 9) has five level 2 child
nodes: transferase (Seqs:153 Score:35.87), lyase (Seqs:67
Score:21.36), oxidoreductase (Seqs:196 Score:124.4),
hydrolase (Seqs:287 Score:37.49) and isomerase (Seqs:78
Score:30.46). Compared to those of BLASTP 2.2.13 [Nov-
27-2005], the DAGs maintain comparatively similar pro-
files, Seqs and Scores.
In comparison, the catalytic activity DAG of the normal
liver proteome (Seqs:810 Score:228.2) (Figure 10), also
has five child nodes: transferase (Seqs:208 Score:53.34),
oxidoreductase (Seqs:331 Score:237.8), hydrolase
(Seqs:220 Score:30.03), isomerases (Seqs:73
Score:26.98), and lyase (Seqs:84 Score:23.17), but the
profiles, Seqs and Scores are, in some cases, very different.
The catalytic activity is lower in HepG2 by 40%, despite
the fact that more HepG2 proteins are annotated: HepG2:
(Molecular Function: Seqs:1742 Score:953.1.0; Catalytic
activity, Seqs:671 Score:161.7) :: Liver: (Molecular Func-
tion: Seqs:1559 Score:953.1; Catalytic activity, Seqs:810
Score:228.2)].
Based on normalized annotation scores, oxidoreductases
are decreased in HepG2 by 56%: HepG2: (oxidoreductase
Catalytic activity DAG of the HepG2 proteome Figure 3
Catalytic activity DAG of the HepG2 proteome. BLAST searches were carried out with BLASTP 2.2.13 [Nov-27-2005].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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activity, Seqs:196 Score:124.4) :: Liver: (oxidoreductase
activity, Seqs:331 Score:237.8)]. Expanded views of the
oxidoreductase DAGs are shown in Figure 11. Again, the
node filter is fixed at 30 for both HepG2 and liver DAGs.
It is seen that four child nodes are present in HepG2 oxi-
doreductase node: electron carrier activity (Seqs:81
Score:75.4), disulfide oxidoreductase activity (Seqs:41
Score:32.59), oxidoreductase activity, acting on CHOOH
group of donors (Seqs:66 Score:41.83), and GO:0016491
(Seqs:4).
The normal liver oxidoreductase has eight child nodes:
oxidoreductase activity, acting on CH-OH group of
donors (Seqs:130 Score:104.5.0), oxidoreductase activity,
acting on paired electron donors, with incorporation or
reduction of molecular oxygen (Seqs:46 Score:28.78),
monooxygenase activity (Seqs:43 Score:28.75), oxidore-
ductase activity, acting on the aldehyde or oxo group of
donors (Seqs:48 Score:31.75), electron carrier activity
(Seqs:130 Score:126.4), GO:0016491 (Seqs:5), disulfide
oxidoreductase activity (Seqs:39 Score:35.4), and oxidore-
ductase activity, acting on CH-CH group of donors
(Seqs:66 Score:25.25).
Additional evidence in support of down-regulation of oxi-
doreductases in HepG2 cells are provided by intramolecu-
lar oxidoreductase activities, shown in Figure 12. The
sequences and scores are remarkably similar to the values
obtained with BLASTP 2.2.13 [Nov-27-2005] analyses of
Figure 6: HepG2: (intra-molecular oxidoreductase activ-
ity, Seqs:25 Score:9.0) :: Liver: (intramolecular oxidore-
ductase activity, Seqs:39 Score:14.04)].
Discussion
Oxidoreductase enzymes are extremely diverse in their
structures, functions, cellular distribution and biochemi-
cal transformations they mediate. In fact, they are subdi-
vided into 22 classes, based on the type of biochemical
reaction pathway they catalyze [46]. One unique feature
of oxidoreductases, however, is that they are strongly
down-regulated in hepatic neoplasia. The exact reasons
and/or molecular mechanisms are not known. Their fun-
damental roles as mediators of biochemical redox reac-
tions may offer clues, however, although conclusive
empirical evidence is scanty.
One possible clue may be found in the metabolic path-
ways of purine biosynthesis [47]. In fact, oxidoreductase
enzymes that catabolize critical intracellular metabolites
Catalytic activity DAG of the normal human liver proteome Figure 4
Catalytic activity DAG of the normal human liver proteome. BLAST searches were carried out with BLASTP 2.2.13 
[Nov-27-2005].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Down-regulation of oxidoreductases in HepG2, when compared to normal human liver Figure 5
Down-regulation of oxidoreductases in HepG2, when compared to normal human liver. Oxidoreductase DAG for 
HepG2 (Panel A), and normal human liver (Panel B). Intramolecular oxidoreductase activity is down-regulated in HepG2, when 
compared with normal human liver. Node filter = 30, for both HepG2 and Normal Human Liver. BLAST searches were carried 
out with BLASTP 2.2.13 [Nov-27-2005].
Isomerase activity for HepG2 DAG (Panel A) and normal human liver proteomes (Panel B) Figure 6
Isomerase activity for HepG2 DAG (Panel A) and normal human liver proteomes (Panel B). BLAST searches car-
ried out with BLASTP 2.2.13 [Nov-27-2005].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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DB-Resources of mapping, for HepG2 (Panel A), and Normal Human Liver (Panel B), showing the databases where mapping  found the Ontologies that are presented in Additional Files 6 and 7, respectively Figure 7
DB-Resources of mapping, for HepG2 (Panel A), and Normal Human Liver (Panel B), showing the databases 
where mapping found the Ontologies that are presented in Additional Files 6 and 7, respectively. With BLASTP 
2.2.15 [Oct-15-2006], mapping now includes RefSeq. Ontologies are found in four databases: GR, UniProt, UNIPROT and Ref-
Seq. Ontologies found in this mapping are much less – almost half of the number found previously in Figure 1 (Panels A and B).Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Evidence code distribution, found by Mapping, for the HepG2 and normal human liver proteomes Figure 8
Evidence code distribution, found by Mapping, for the HepG2 and normal human liver proteomes. BLAST pro-
gram, BLASTP 2.2.15 [Oct-15-2006] was used.Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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of de novo biosynthesis of purines are consistently docu-
mented to be highly down-regulated in hepatomas, the
extent of which correlates with the degree and the severity
of malignancy and tumor progression. At the same time,
the enzymes that channel these strategic intermediates
toward de novo biosynthesis of purine nucleotides and
DNA/RNA are found to increase with increasing severity
of the disease.
In non-neoplastic hepatocytes, the balance between these
two opposing forces shifts in favor of greater catabolic
capacity. In hepatic neoplasia, however, an apparent
reprogramming of gene expression shifts the balance
toward preponderance of anabolic capacity: a survival
mechanism that confers selective advantage to cancer cells
in an effort to maximize their proliferative potentials.
Rapidly proliferating cancer cells have elevated demand
for nucleic acid biosynthesis; they are critically dependent
on abundant supply of key purine metabolites that are
needed for the de novo biosynthesis of purine nucleotides
adenine and guanine.
One such metabolite is inosine monophosphate (IMP),
which is a precursor for de novo biosynthesis of purine
nucleotides [14]. In hepatic neoplasia, all the key enzymes
involved in the biosynthesis and utilization of IMP are
found to increase [48-50], whereas the rate-limiting oxi-
doreductase enzyme of IMP catabolism, xanthine oxidase
(EC:1.2.3.2), decreases sharply, in direct proportion to the
severity of the disease [13,14].
Another example is 10-formyltetrahydrofolate (10-
formyl-THF) [25,51]. 10-formyl-THF is a critically needed
precursor for two reactions of de novo biosynthesis of
purine nucleotides [52]. Its substrate is the oxidoreductase
enzyme 10-formyltetrahydrofolate Dehydrogenase (FDH;
EC:1.5.1.6), which removes its formyl group (Figure 13).
Thus, FDH plays a key role in the control of the intracellu-
lar 10-formyl-THF pool [51]. During malignant transfor-
mation and tumor progression, intracellular
concentration of FDH is dramatically down-regulated by
gene reprogramming [25,53], leading to a build-up of
Catalytic activity DAG of the HepG2 proteome Figure 9
Catalytic activity DAG of the HepG2 proteome. BLAST searches were carried out with BLASTP 2.2.15 [Oct-15-2006].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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intracellular 10-formyl-THF pool. Concomitantly, the key
enzymes of the de novo and salvage pathways of purine
biosynthesis are increased [53].
Oxidoreductase scavenger enzyme systems of catalase
(CAT), superoxide-dismutase (SOD), and glutathione
peroxidase (GSH-Px) are the most important enzymatic
free radical defense mechanisms that protect cells from
apoptosis and other damaging effects oxidative stress.
Research now show that CAT [19,21,54,55], SOD
[23,24,56] and GSH-Px [16,54,56] are strongly down-reg-
ulated in Hepatocellular carcinoma, the putative explana-
tion being likely, again, a genetic reprogramming in favor
of high proliferative capacity of the cancer cells. Indeed,
cancer cells evolve a variety of survival adaptations to
boost their proliferative capacity.
Abundant supply of oxygen free radicals is highly needed
by rapidly proliferating cancer cells [57]. And, cancer cells
avoid apoptosis caused by excessive oxygen free radicals
by activating protein kinase B (PKB; also known as c-Akt)
which protects them from apoptosis [58].
Another possible explanation for the inhibition of CAT in
hepatoma was suggested to stem from the secretion of a
toxohormone from neoplastic tissue [59].
Conclusion
Comparative proteomics and Gene Ontology analyses of
the HepG2 Cells and normal human liver proteomes
show that oxidoreductase enzymes are down-regulated in
HepG2 cells by 57%. Specifically, when Gene Ontology
Molecular Function annotations are plotted as Directed
Acyclic Graphs, it is seen that the oxidoreductase activity
parent node of the liver proteome consists of 331 protein
sequences, 7 child nodes and an annotation score of
188.9, whereas that of HepG2 has 188 protein sequences,
3 child nodes and an annotation score of only 91.9.
Down-regulation of oxidoreductases in Hepatocellular
carcinoma, when compared to surrounding non-neoplas-
tic liver tissues, is well-documented in the literature, with
examples that include 10-Formyltetrahydrofolate dehy-
drogenase, cytochrome oxidase, succinate dehydrogenase,
monoamine oxidase, cytochrome P450, catalase, urate
oxidase, D-amino acid oxidase, L-alpha-hydroxy acid oxi-
Catalytic activity DAG of the normal human liver proteome Figure 10
Catalytic activity DAG of the normal human liver proteome. BLAST searches were carried out with BLASTP 2.2.15 
[Oct-15-2006].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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dase, xanthine oxidase and (Cu/Zn) superoxide dis-
mutase.
The exact reasons for this repression are not known, but
one plausible explanation has been suggested to be an
apparent reprogramming of gene expression, which shifts
the metabolic balance toward preponderance of anabolic
capacity over catabolism. This appears to be a survival
mechanism which confers powerful selective advantage to
cancer cells in an effort to maximize their proliferative
potentials. Another possible explanation was suggested to
stem from the secretion of a toxohormone by the cancer
cells themselves (observed only in the case of inhibition
of catalase in hepatoma).
This work is the first report on the use of proteomics, Gene
Ontology and Directed Acyclic Graph representations to
detect and quantify the repression of oxidoreductase
enzymes in hepatoma. Detection of differential enzyme
expressions between a tumor proteome and its non-neo-
plastic counterpart may offer the possibility of being a
new prognostic marker for Hepatocellular carcinoma.
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Down-regulation of oxidoreductases in HepG2, when compared to normal human liver Figure 11
Down-regulation of oxidoreductases in HepG2, when compared to normal human liver. Oxidoreductase DAG for 
HepG2 (Panel A), and normal human liver (Panel B). Node filter = 30, for both HepG2 and Normal Human Liver. BLAST 
searches were carried out with BLASTP 2.2.15 [Oct-15-2006].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Isomerase activity for HepG2 DAG (Panel A) and normal human liver proteomes (Panel B) Figure 12
Isomerase activity for HepG2 DAG (Panel A) and normal human liver proteomes (Panel B). Intramolecular oxi-
doreductase activity is down-regulated in HepG2, when compared to normal human liver. BLAST searches were carried out 
with BLASTP 2.2.15 [Oct-15-2006].Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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Additional file 1
HepG2_1795 unique proteins identified in the MudPIT mass spectra 
of HepG2 cells. When Bioworks version 3.2 searched the HepG2 Mud-
PIT data against NCBI nr database, 77831 hits were returned. Then, 
upon post-search processing and validation, only 1795 out of the original 
hits are confirmed. The post-search processing is based upon the criteria 
that: only peptides identified as possessing fully tryptic termini (containing 
up to two missed internal trypsin cleavage sites), with cross-correlation 
scores (Xcorr) greater than 1.9 for singly charged peptides, 2.3 for doubly 
charged peptides and 3.75 for triply charged peptides, are used for peptide 
identification. In addition, the delta-correlation scores (ΔCn) must be 
greater than 0.1 for peptide identification, and protein probability was set 
at ≤ 1e-002.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S1.xls]
Additional file 2
Human Liver_1819 unique proteins identified in the MudPIT mass 
spectra of normal human liver tissue. post-search criteria are identical 
to those of the HepG2 proteome of Additional File 1: Only 1819 vali-
dated, unique proteins are retained out of the 79961 original hits of the 
normal human liver proteome.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S2.xls]
Additional file 3
MudPIT mass spectra of HepG2 cells (left) and normal human liver 
tissue (right). There are twenty-four nano-LC/ESI-MS/MS spectra, two 
of which are 1D nano-LC/ESI-MS/MS. Twenty-two are 2D nano-LC/
ESI-MS/MS spectra. Each MudPIT experiment consists of a 12-cycle run 
in which a 60-minute nano-LC/ESI-MS/MS gradient is run for each of: 
1D, 2D, 2D (0 mM NH4COO), 2D (25 mM NH4COO), 2D (50 mM 
NH4COO), 2D (75 mM NH4COO), 2D (100 mM NH4COO), 2D 
(150 mM NH4COO), 2D (200 mM NH4COO), 2D (250 mM 
NH4COO), 2D (300 mM NH4COO) and 2D (500 mM NH4COO).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S3.tiff]
Additional file 4
HepG2_Sequence Table_BLASTP 2.2.13_ [Nov-27-2005]. The results 
of a Mapping operation are presented in the form of a Sequence Table, 
which consists of nine parameters (Headers): Sequence name, Seq 
description, Length, #hits, Maximum eValue, Similarity mean, number of 
Ontologies (GOs) found, the GO identification numbers of the found 
Ontologies, Enzyme (i.e. Enzyme Commission number).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S4.xls]
Additional file 5
Human Liver_Sequence Table_BLASTP 2.2.13_ [Nov-27-2005]. 
Description of Sequence Table same as for Additional file 4.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S5.xls]
Additional file 6
HepG2_Sequence Table_BLASTP 2.2.15_ [Oct-15-2006]. Description 
of Sequence Table same as for Additional file 4.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S6.xls]
Additional file 7
Human Liver_Sequence Table_BLASTP 2.2.15_ [Oct-15-2006]. The 
results of a Mapping operation are presented in the form of a Sequence 
Table, which consists of nine parameters: Sequence name, Seq description, 
Length, #hits, Maximum eValue, Similarity mean, number of Ontologies 
(GOs) found, the GO identification numbers of the found Ontologies, 
Enzyme (i.e. Enzyme Commission number).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-29-S7.xls]
_Oxidoreductase enzyme 10-formyltetrahydrofolate Dehy- drogenase (FDH; EC:1.5.1.6), removes formyl group from  10-formyltetrahydrofolate (10-formyl-THF) Figure 13
_Oxidoreductase enzyme 10-formyltetrahydrofolate 
Dehydrogenase (FDH; EC:1.5.1.6), removes formyl 
group from 10-formyltetrahydrofolate (10-formyl-
THF). 10-formyl-THF is a critically needed precursor for 
two reactions of de novo biosynthesis of purine nucleotides.Proteome Science 2008, 6:29 http://www.proteomesci.com/content/6/1/29
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